Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bucaloiu, I. D.
Right arrow Articles by Fata, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bucaloiu, I. D.
Right arrow Articles by Fata, F.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 21, Issue 12 (June), 2003: 2442-2443
© 2003 American Society for Clinical Oncology


DIAGNOSIS IN ONCOLOGY

Small-Cell Cancers, and an Unusual Reaction to Chemotherapy

CASE 4. FLUOROURACIL-RELATED SMALL BOWEL VASCULITIS

Ion D. Bucaloiu, Srinivasan Dubagunta, Krishna K Pachipala, Nazmi Kamal, Farid Fata

Geisinger Medical Center, Danville, PA

Fluorouracil (FU) is one of the most commonly used chemotherapeutic agents in clinical oncology practice, alone or in differentcombinations. In colorectal cancer the addition of leucovorin (LV) to FU resulted in improved patient survival, improved objectivetumor response, and better quality of life.1 We report a case of ischemic small-bowel injury in a patient who received adjuvantchemotherapy with oxaliplatin (OP), FU, and LV and was found to have angiographic evidence of vasculitis in the superiormesenteric artery (SMA) territory. This will add to the series of patients reported with FU-related or FU-induced vascular injury tothe small bowel.2

A 73-year-old male underwent a left hemicolectomy for stage III colon cancer. He was enrolled in an adjuvant chemotherapyresearch protocol consisting of FU 500 mg/m2 intravenous (IV) weekly boluses, each administered during 1 hour; LV 500 mg/m2IV weekly infusions, each administered during 2 hours; and OP 85 mg/m2 IV infusions every 2 weeks for 6 weeks, followed by 2weeks of rest. After the third cycle of FU, LV, and OP, he presented with weakness, diarrhea, abdominal cramps, and poor appetite.His abdomen was distended and he had heme-positive stools. Stool cultures and Clostridium difficile toxin antigen were negative.He was not neutropenic. Colonoscopy revealed dusky edematous changes in the ascending colon and focal ulceration with patchysubmucosal hemorrhages in the distal ileum (Figs 1Go and 2Go, arrows). Biopsies of the colon mucosa showed densely neutrophilicinfiltrates of the lining epithelium and associated mild focal cryptitis. An SMA angiogram was performed and it revealed beadingin ileal branches, consistent with the ischemic territory (Fig 3Go). Vasculitis serologies were negative. The patient was treatedconservatively with hydration and IV antibiotics, and he was later rechallenged with a 20% reduction of FU dose, with no recurrenceof his symptoms in long-term follow-up.



View larger version (150K):
[in this window]
[in a new window]
 
Fig 1. Distal ileum endoscopy. Superficial mucosal erosions and ulcerations arrow).

 


View larger version (160K):
[in this window]
[in a new window]
 
Fig 2. Dusky edematous changes in the ascending colon giving the appearance of ischemic colitis (arrow).

 


View larger version (201K):
[in this window]
[in a new window]
 
Fig 3. Superior mesentery artery angiogram showing a beading appearance of ileal branches (arrow).

 
We present a case of ischemic bowel injury in the SMA territory in a patient who received adjuvant FU-based therapy for stageIII colon cancer. Vascular effects of FU have been reported mainly in patients who developed cardiotoxicity.3 The relationshipbetween the type of administration bolus versus continuous infusion is not clear, although the majority of patients who developedcardiotoxicity received the drug continuously.3–5

A series of patients with resected adenocarcinoma of colon who were treated with FU and LV and developed severe erosions andsuperficial ulcerations in the ileum has been described.2 These patients were successfully rechallenged with a 20% reduction of FUdose without further toxicities. The mechanisms involved are thought to be multifactorial, including alteration of local mucosal bloodflow4,6 and thrombogenic7 and vasospastic3,8 effects of FU on the vascular epithelium. Indeed, Mosseri et al8 demonstrated in vitrothat FU causes direct endothelial-independent vasoconstriction related to activation of protein kinase C.

Our patient had superficial erosions and ulcerations in the ileum (Fig 3Go) as well as ischemic appearance of the colon. The characteristic findings of beading on the angiogram suggest an underlying ischemic mechanism related to FU-based therapy.

REFERENCES

Poon M, O’Connel MJ, Wieand HS, et al: Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967–1972, 1991[Abstract/Free Full Text]

Fata F, Ron IG, Kemeny N, et al: 5-Fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer 86:1129–1134, 1999[CrossRef][Medline]

Gradishar WJ, Vokes EE: 5-Fluorouracil cardiotoxicity: A critical review. Ann Oncol 1:409–414, 1990[Abstract/Free Full Text]

Narsete Th, Ansfield F, Wirtanen G, et al: Gastric ulceration in patients receiving intrahepatic infusion of 5-fluorouracil. Ann Surg 186:734–737, 1977[Medline]

Suda K, Seki T, Kano Y, et al: Continuous 5-fluorouracil infusion acute causing gastric mucosal lesions. Endoscopy25:426–427, 1993[Medline]

Kakinuma S, Ohwada S: Gastric mucosal blood flow and gastric secretion following intravenous administration of 5-fluorouracil in rats. Cancer Chemother Pharmacol 39:357–360, 1997[CrossRef][Medline]

Kuzel T, Esparaz B, Green D, et al: Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 65:885–889, 1990[CrossRef][Medline]

Mosseri M, Fingert HJ, Vartikosski L, et al: In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase c-mediated vasoconstriction of vascular smooth muscle. Cancer Res 53:3028–3033, 1993[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bucaloiu, I. D.
Right arrow Articles by Fata, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bucaloiu, I. D.
Right arrow Articles by Fata, F.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2003 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online